Literature DB >> 8424523

Management of pain in the cancer patient.

M A Ashburn1, A G Lipman.   

Abstract

The pain experience of the cancer patient is the result of many factors, including nociceptive sources, specific pain syndromes, and behavioral contributions. Careful evaluation of the patient is necessary to identify the contributors to the patient's pain experience and to select treatment modalities which address the underlying causes. For patients who are experiencing poorly controlled pain as a result of cancer, therapy often includes multiple management strategies involving more than one discipline. Therefore, an interdisciplinary approach may be more useful for pain management. Disciplines and specialties. involved in such care commonly include anesthesiologists, oncologists, psychiatrists, psychologists, physical therapists, pharmacists, nurses, and social workers. The locus of control often influences how patients respond to their physicians' advice. Patients with a strong internal locus of control usually want to participate actively in treatment decisions. Such patients often resent having decisions made about their treatment without their participation. A lack of sense of control can exacerbate such patients' pain and limit compliance with recommended treatments. Drug therapy is the mainstay of cancer pain management. The therapy should be individualized to the patient, and medications should be selected for specific indications. The WHO three-step analgesic ladder should be used as a guide in selecting analgesics. Drugs should be administered by mouth unless it is impossible to do so, and drug costs should be considered when selecting analgesic medications. Doses should be titrated to response. Adjuvant drug therapy should be considered early and implemented when indicated. Practitioners should be familiar with the medications prescribed and be alert for the appearance of adverse side effects. Patients should be monitored and reassessed continuously. A thorough diagnostic work-up should be completed for new symptoms when indicated. For patients with specific pain syndromes, or for whom drug therapy has not been successful, local anesthetic and neurolytic block therapy and more invasive drug delivery systems (e.g., epidural catheters) should be considered. Although cure may not be attainable in many cancer patients, the obligations of health professionals to these patients are no less than to patients for whom a cure is achievable. Effective pain management has a profound impact on the quality of life, and may give the patient the opportunity to face death with dignity and reduced suffering.

Entities:  

Mesh:

Year:  1993        PMID: 8424523

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  10 in total

1.  Skin pretreatment with an Er:YAG laser promotes the transdermal delivery of three narcotic analgesics.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Chia-Lang Fang; Ching-Ru Liu; Jia-You Fang
Journal:  Lasers Med Sci       Date:  2007-03-03       Impact factor: 3.161

2.  Behavioral medicine interventions can improve the quality-of-life and health of persons with HIV disease.

Authors:  K J Sikkema; J A Kelly
Journal:  Ann Behav Med       Date:  1996-03

Review 3.  Oral transmucosal fentanyl. Help or hindrance?

Authors:  M A Ashburn; J B Streisand
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 4.  Management of pain in the elderly at the end of life.

Authors:  Eric Prommer; Brandy Ficek
Journal:  Drugs Aging       Date:  2012-04-01       Impact factor: 3.923

Review 5.  Choosing the right analgesic. A guide to selection.

Authors:  Timothy G Bushnell; Douglas M Justins
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 6.  Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.

Authors:  Craig A Kornick; Juan Santiago-Palma; Natalia Moryl; Richard Payne; Eugenie A M T Obbens
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers.

Authors:  Susanne Ammon; Claudia Marx; Christoph Behrens; Ute Hofmann; Thomas Mürdter; Ernst-Ulrich Griese; Gerd Mikus
Journal:  BMC Clin Pharmacol       Date:  2002-02-27

8.  Clinical Usefulness of Long-term Application of Fentanyl Matrix in Chronic Non-Cancer Pain: Improvement of Pain and Physical and Emotional Functions.

Authors:  Jaewon Lee; Joon Shik Yoon; Jae Hyup Lee; So-Hak Chung; Kyu-Yeol Lee; Young Yul Kim; Jong Moon Kim; Min Ho Kong; Ung Gu Kang; Ye-Soo Park
Journal:  Clin Orthop Surg       Date:  2016-11-04

9.  Intrathecal betamethasone for cancer pain: A study of its analgesic efficacy and safety.

Authors:  Hitoshi Taguchi; Keiko Oishi; Koh Shingu; Hideo Matsumoto; Munehiro Masuzawa
Journal:  Acta Anaesthesiol Scand       Date:  2018-12-07       Impact factor: 2.105

Review 10.  Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain.

Authors:  Tracy L Skaer
Journal:  J Pain Res       Date:  2014-08-19       Impact factor: 3.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.